ArticleAlimentary pharmacology & therapeutics2021

Drug survival of anti-TNF agents compared with vedolizumab as a second-line biological treatment in inflammatory bowel disease: results from nationwide Swedish registers.

Sara Rundquist et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.